Cepheid Product Pipeline Analysis, Q4, 2019 Update – Partnership with Small & Large Biopharmaceutical Companies to Develop Therapies in Anti-Infective, Critical Infectious Disease & Oncology Areas – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cepheid – Product Pipeline Analysis, 2019 Update” company profile has been added to ResearchAndMarkets.com’s offering.

Summary

Cepheid, a subsidiary of Danaher Corporation, is a molecular diagnostic company that develops, manufactures and markets molecular systems and tests for clinical and non-clinical markets. The company offers in vitro diagnostic tests for health care associated infections, critical infectious diseases, sexual health, and oncology and genetics; molecular diagnostic systems; and reagents and parts. Cepheid distributes its products directly and through a network of distributors across Americas, Asia, Europe, Africa and the Middle East regions. The company has partnership with small and large biopharmaceutical companies to develop therapies in anti-infective, critical infectious disease and oncology areas. Cepheid is headquartered in Sunnyvale, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

• The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
• The report analyzes all pipeline products in development for the company Cepheid
• The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
• The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
• The report provides detailed description of products in development, technical specification and functions
• The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
• Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
• To formulate effective Research & Development strategies
• Develop market-entry and market expansion strategies
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
• Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Key Topics Covered:

• Cepheid Company Overview
• Cepheid Company Snapshot
• Cepheid Pipeline Products and Ongoing Clinical Trials Overview
• Cepheid – Pipeline Analysis Overview
• Business Description
• Cepheid – Key Facts
• Cepheid – Major Products and Services
• Cepheid Pipeline Products by Development Stage
• Cepheid Ongoing Clinical Trials by Trial Status
• Cepheid Pipeline Products Overview
• GeneXpert – Xpert HPV CLIA Waived
• GeneXpert Omni Clinical Trial
• GeneXpert Omni – Flu/RSV CW
• GeneXpert Omni – HIV-1 Qualitative Test
• GeneXpert Omni – MTB/RIF
• GeneXpert Omni – Xpert HPV
• GeneXpert Omni – Xpert MTB/RIF Ultra
• GeneXpert Omni – Xpress Flu CW
• GeneXpert Omni – Xpress GAS CW
• GeneXpert Omni – Xpress Pertussis CW
• GeneXpert Omni – Xpress Vaginitis/Vaginosis CW
• POC Catridge – Viral Hemorrhagic Fever
• Urine Based Screening Test – Cervical Cancer
• Xpert BCR-ABL Ultra – Acute Lymphocytic Leukemia
• Xpert BCR-ABL Ultra – Solid Tumors
• Xpert Bladder Cancer Asymptomatic Assay
• Xpert Bladder Cancer Monitor Test Clinical Trial
• Xpert Bladder Cancer Symptomatic Assay
• Xpert Breast CA Prognostic Signature Assay
• Xpert Breast CA Stratifier Assay
• XPERT CLL Monitoring Test
• Xpert CMV Viral Load Assay
• Xpert CT/NG FluroQ Resistant Trichomonas Assay
• Xpert CT/NG LBC Assay
• Xpert EBV / NPC Screen
• Xpert EGFR Monitor (Lung) Test
• Xpert GBS Ultra
• Xpert Group A Strep Assay
• Xpert HCV Quant Assay
• Xpert HSV 1 And 2 Test
• Xpert Lung CA Early Detection Test
• Xpert Microbial ID Assay
• Xpert MTB/RIF Ultra
• Xpert MTB/XDR Test
• Xpert Next Generation MRSA/SA SSTI Assay
• Xpert Next Generation SA Nasal Complete Assay
• XPERT Pancreatic CA Early Detection Test
• Xpert Pertussis Assay
• Xpert Prostate CA Early Detection Test
• Xpert Respiratory Panel Assay
• Xpert Sepsis Fungal Assay
• Xpert Vaginitis Assay
• Xpert VZV Assay
• Cepheid – Key Competitors
• Cepheid – Key Employees
• Cepheid – Key Employee Biographies
• Cepheid – Locations And Subsidiaries
• Head Office
• Other Locations & Subsidiaries
• Recent Developments
• Cepheid, Recent Developments
• Oct 02, 2019: Cepheid Receives FDA Clearance for Xpert BCR-ABL Ultra Test
• Jun 10, 2019: Xpert Ultra test for diagnosing TB now included in Cochrane Review
• May 29, 2019: Cepheid receives FDA clearance for extragenital claims for Xpert CT/NG test
• May 24, 2019: FDA clears diagnostic tests for chlamydia and gonorrhoea
• Apr 27, 2019: SpeeDx and Cepheid announce test partnership
• Dec 20, 2018: Cepheid receives CE-IVD clearance for Xpert HBV Viral Load
• Sep 24, 2018: Johnson & Johnson announces 10-year initiative to help end tuberculosis, the World’s 1 Infectious Killer
• Sep 19, 2018: Cepheid Receives CE-IVD clearance for Xpert HCV VL Fingerstick
• Jul 30, 2018: FDA clears Cepheid Xpert Xpress Flu/RSV test
• Jul 26, 2018: Cepheid Receives FDA Clearance and CLIA Waiver for Xpert Xpress Flu/RSV Test
• Appendix
• Methodology
• About the Author
• Contact Us
• Disclaimer

Companies Mentioned

• Hologic Inc
• F. Hoffmann-La Roche Ltd
• bioMerieux SA
• Abbott Laboratories
• Meridian Bioscience Inc
• Qiagen NV
• Binx Health Inc
• Life Technologies Corp
• GenMark Diagnostics Inc
• Becton Dickinson and Co
• Luminex Corp

For more information about this company profile visit https://www.researchandmarkets.com/r/2p21gz

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900